J. Goldman & CO LP Amylyx Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $2 Million - $3.06 Million	-165,878 Reduced 89.71%	19,029 $280,000
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $1.55 Million - $2.01 Million	85,567 Added 86.14%	184,907 $3.39 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $651,680 - $975,968	31,062 Added 45.49%	99,340 $2.14 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $627,243 - $926,491	22,636 Added 49.59%	68,278 $2 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $1.36 Million - $1.79 Million	45,642 New	45,642 $1.69 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.